Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
PEMBROLIZUMAB BERAHYALURONIDAS (CPT yPEM56) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved June 28, 2026 , from http://ppman.hank.ai/transparency/procedure/yPEM56/by-state?code_type=CPT
“PEMBROLIZUMAB BERAHYALURONIDAS (CPT yPEM56) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/yPEM56/by-state?code_type=CPT. Accessed
June 28, 2026 .
“PEMBROLIZUMAB BERAHYALURONIDAS (CPT yPEM56) by State,” HANK Price Transparency ,
accessed June 28, 2026 ,
http://ppman.hank.ai/transparency/procedure/yPEM56/by-state?code_type=CPT.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
CPT · across United States
yPEM56 — Pembrolizumab Berahyaluronidas
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$103,951
National median
$44,757 – $115,501
IQR (p25 – p75)
1
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for yPEM56 (CPT), with interquartile range
State Median p25 p75
PA $103,951 $44,757 $115,501